See more : CuriosityStream Inc. (CURI) Income Statement Analysis – Financial Results
Complete financial analysis of Korro Bio, Inc. (KRRO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Korro Bio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- China Metal Resources Utilization Limited (1636.HK) Income Statement Analysis – Financial Results
- Gyre Therapeutics, Inc. (GYRE) Income Statement Analysis – Financial Results
- Costar Technologies, Inc. (CSTI) Income Statement Analysis – Financial Results
- Chain Bridge I (CBRGW) Income Statement Analysis – Financial Results
- Advantagewon Oil Corporation (AOC.CN) Income Statement Analysis – Financial Results
Korro Bio, Inc. (KRRO)
About Korro Bio, Inc.
Korro Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases. Korro Bio, Inc. is based in Cambridge, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 14.07M | 36.98M | 28.95M | 0.00 | 0.00 |
| Cost of Revenue | 3.63M | 2.51M | 3.84M | 1.58M | 16.81M | 654.00K | 531.00K |
| Gross Profit | -3.63M | -2.51M | 10.23M | 35.40M | 12.13M | -654.00K | -531.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 72.70% | 95.73% | 41.92% | 0.00% | 0.00% |
| Research & Development | 57.25M | 42.20M | 23.81M | 36.66M | 18.33M | 11.58M | 11.79M |
| General & Administrative | 27.28M | 16.80M | 11.69M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 27.28M | 16.80M | 11.69M | 26.30M | 14.48M | 6.71M | 3.99M |
| Other Expenses | 0.00 | 976.00K | 13.54M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 84.53M | 59.00M | 35.49M | 62.95M | 32.81M | 18.29M | 15.78M |
| Cost & Expenses | 84.53M | 59.00M | 35.49M | 64.53M | 49.62M | 18.94M | 16.31M |
| Interest Income | 0.00 | 947.00K | 0.00 | 994.00K | 1.78M | 0.00 | 0.00 |
| Interest Expense | 0.00 | 118.00K | 0.00 | 0.00 | 0.00 | 106.00K | 174.00K |
| Depreciation & Amortization | 3.63M | 2.51M | 3.84M | 1.58M | 813.00K | 654.00K | 531.00K |
| EBITDA | -80.90M | -56.49M | -33.90M | -24.90M | -17.93M | -18.41M | -19.53M |
| EBITDA Ratio | 0.00% | 0.00% | -240.97% | -70.22% | -68.62% | 0.00% | 0.00% |
| Operating Income | -84.53M | -59.00M | -35.49M | -27.55M | -20.68M | -18.94M | -16.31M |
| Operating Income Ratio | 0.00% | 0.00% | -252.30% | -74.49% | -71.42% | 0.00% | 0.00% |
| Total Other Income/Expenses | 3.39M | 976.00K | 13.54M | 1.07M | 1.93M | -224.00K | -3.93M |
| Income Before Tax | -81.15M | -58.02M | -21.96M | -26.48M | -18.75M | -19.17M | -20.24M |
| Income Before Tax Ratio | 0.00% | 0.00% | -156.08% | -71.59% | -64.76% | 0.00% | 0.00% |
| Income Tax Expense | 27.00K | 10.00K | 2.00K | 35.00K | 0.00 | 0.00 | 1.00 |
| Net Income | -81.17M | -58.03M | -21.96M | -26.51M | -18.75M | -19.17M | -20.24M |
| Net Income Ratio | 0.00% | 0.00% | -156.09% | -71.68% | -64.76% | 0.00% | 0.00% |
| EPS | -53.09 | -227.58 | -4.94 | -41.10 | -30.39 | -30.57 | -32.27 |
| EPS Diluted | -53.08 | -227.42 | -4.94 | -41.10 | -30.39 | -30.57 | -32.27 |
| Weighted Avg Shares Out | 1.53M | 255.00K | 4.45M | 645.06K | 616.89K | 627.09K | 627.09K |
| Weighted Avg Shares Out (Dil) | 1.53M | 255.17K | 4.45M | 645.06K | 616.89K | 627.09K | 627.09K |
Does Korro Bio, Inc. (KRRO) Have the Potential to Rally 59.66% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 59.7% in Korro Bio, Inc. (KRRO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate...
Korro Bio Highlights Data for its Lead Program in Alpha-1 Antitrypsin Deficiency (AATD) and Progress Across its RNA Editing Portfolio
CAMBRIDGE, Mass., Jan. 18, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, presented new data for KRRO-110 and reported...
Korro to Present at the 42nd Annual J.P. Morgan Healthcare Conference
CAMBRIDGE, Mass., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO) today announced that Chief Executive Officer and President, Ram Aiyar, Ph.D., will present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024...
Korro Announces Selection of its First Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company focused on developing a new class of genetic medicines for both rare and highly prevalent diseases, has nominated its first development candidate, KRRO-110,...
These 3 Biotech Stocks More Than Doubled in November. Can They Fly Even Higher in 2024?
Korro Bio is working on an RNA-editing platform, and its stock price shot up 171% in November. Gyre Therapeutics is a commercial-stage drugmaker in China that could expand into the lucrative U.S. market.
Source: https://incomestatements.info
Category: Stock Reports